Ischemic Preconditioning and Atenolol on Lung Injury After Intestinal Ischemia and Reperfusion in Rats

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BONSERVIZI, W. G. S.
SAURIM, R.
FELIX, G. A. A.
SILVA, S. M. da
TAHA, M. O.
Citação
TRANSPLANTATION PROCEEDINGS, v.46, n.6, p.1862-1866, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of this study was evaluate the beta blocker atenolol (AT) and ischemic preconditioning (IPC) strategies for tissue protection against systemic effects of intestinal ischemia (I) and reperfusion (R) injury. Forty-two rats were pretreated with AT (1.5 mg . kg(-1)), 0.9% saline solution (SS; 0.1 mL), or IPC and then subjected to prolonged occlusion of the superior mesenteric artery for 60 minutes leading to I followed or not by 120 minutes of R, according to the group. For IPC, 5 minutes of I prior to 10 minutes of R were established. After this process of I or I-R, the right lung of each animal was adequately prepared for staining with hematoxylin and eosin and subsequent histologic analysis for quantification of inflammatory infiltrate was done. The left lung was frozen and prepared for assessment of oxidative stress by the quantification of thiobarbituric acid-reactivity substances (TBARS). Histologic analysis showed an important inflammatory infiltrate in the I-R + SS (I-R + SS 4.5), which was significantly (P < .05) reduced by IPC (I-R + IPC = 3.0) or AT (I-R + AT = 3.0). Likewise, the TBARS levels were decreased by both strategies (I-R + SS = 0.63; I-R + IPC = 0.23; I-R + AT = 0.38; P < .05). Our results showed that AT and IPC attenuate pulmonary lesions caused by intestinal I and R process.
Palavras-chave
Referências
  1. Abu-Elmagd K, 2003, P NUTR SOC, V62, P727, DOI 10.1079/PNS2003288
  2. ARNOULD T, 1993, AM J PHYSIOL, V264, pC1102
  3. Azeredo Marcelo Aragão Insuellas de, 2008, Acta Cir Bras, V23, P425
  4. Beheshtian A, 2006, ANN PLAS SURG, V57, P94, DOI 10.1097/01.sap.0000214872.13634.d4
  5. Belzer FO, 1998, TRANSPLANTATION, V45, P670
  6. BLANKENSTEIJN JD, 1991, HEPATOLOGY, V13, P1235, DOI 10.1016/0270-9139(91)92496-U
  7. Campos VF, 2012, TRANSPL P, V44, P1313
  8. CARDEN DL, 1993, J APPL PHYSIOL, V75, P2529
  9. Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6
  10. Collard CD, 1999, MOL IMMUNOL, V36, P941, DOI 10.1016/S0161-5890(99)00116-9
  11. Cutrin JC, 2002, FREE RADICAL BIO MED, V33, P1200, DOI 10.1016/S0891-5849(02)01017-1
  12. Deng Z, 2003, CELL, V1, P405
  13. Dessy C, 2005, CIRCULATION, V112, P1198, DOI 10.1161/CIRCULATIONAHA.104.532960
  14. Ferencz A, 2002, SURGERY, V132, P877, DOI 10.1067/msy.2002.129910
  15. FEUERSTEIN GZ, 1995, EUR HEART J, V16, P38
  16. KIRCH W, 1982, EUR J DRUG METAB PH, V7, P81
  17. Guillaumon AT, 2013, ACTA CIR BRAS, V28, P288, DOI 10.1590/S0102-86502013000400009
  18. Gupta S, 2008, CARDIOVASC THER, V26, P189, DOI 10.1111/j.1755-5922.2008.00054.x
  19. Harkin DW, 2002, J VASC SURG, V35, P1264, DOI 10.1067/mva.2002.121981
  20. Ignarro LJ, 2008, CARDIOVASC THER, V26, P115, DOI 10.1111/j.1527-3466.2008.00044.x
  21. Jaeschke H, 2003, AM J PHYSIOL-GASTR L, V284, pG15, DOI 10.1152/ajpgi.00342.2002
  22. Kamp O, 2010, DRUGS, V70, P41, DOI 10.2165/11530710-000000000-00000
  23. KLAUSNER JM, 1989, CIRC RES, V64, P1178
  24. KLAUSNER JM, 1988, ANN SURG, V208, P761, DOI 10.1097/00000658-198812000-00015
  25. KOMATSU H, 1992, AM J PHYSIOL, V262, pG669
  26. LOPEZ BL, 1995, PHARMACOLOGY, V51, P165, DOI 10.1159/000139331
  27. Maier R V, 1996, New Horiz, V4, P211
  28. MCCORD JM, 1985, NEW ENGL J MED, V312, P159
  29. McGuill M. W., 1989, ILAR News, V31, P5
  30. MORITA K, 1995, J THORAC CARDIOV SUR, V110, P1245, DOI 10.1016/S0022-5223(95)70011-0
  31. Neary P, 1999, ISCHAEMIA-REPERFUSION INJURY, P123
  32. Weiss Robert, 2006, Vasc Health Risk Manag, V2, P303, DOI 10.2147/vhrm.2006.2.3.303
  33. OHLSTEIN EH, 1993, P NATL ACAD SCI USA, V90, P6189, DOI 10.1073/pnas.90.13.6189
  34. Onody A, 2003, FEBS LETT, V536, P35, DOI 10.1016/S0014-5793(03)00006-1
  35. Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
  36. Parks DA, 1988, AM J PHYSIOL, V254, P768
  37. POGGETTI RS, 1992, J TRAUMA, V32, P723, DOI 10.1097/00005373-199206000-00008
  38. Ramirez P, 2000, CIR ESP, V67, P281
  39. Scannell G, 1996, New Horiz, V4, P179
  40. SCHOENBERG MH, 1993, CRIT CARE MED, V21, P1376, DOI 10.1097/00003246-199309000-00023
  41. SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122
  42. SLATER TF, 1984, BIOCHEM J, V222, P1
  43. Sola A, 2001, ANN SURG, V234, P98, DOI 10.1097/00000658-200107000-00015
  44. Souza Filho MV, 2010, EUR J PLAST SURG, V33, P147
  45. Souza MVP, 2009, BRAZ J MED BIOL RES, V42, P921, DOI 10.1590/S0100-879X2009005000025
  46. Sthal RF, 1989, J SURG RES, V47, P97
  47. Taha MO, 2010, TRANSPL P, V42, P451, DOI 10.1016/j.transproceed.2010.01.020
  48. Taha MO, 2004, TRANSPLANT P, V36, P289, DOI 10.1016/j.transproceed.2004.01.077
  49. Taha MO, 2012, TRANSPL P, V44, P2304, DOI 10.1016/j.transproceed.2012.07.056
  50. Taha MO, 2004, TRANSPLANT P, V36, P293, DOI 10.1016/j.transproceed.2004.01.095
  51. Terada LS, 1992, AM J PHYSIOL, V263, P394
  52. Um JW, 2005, J SURG RES, V124, P289, DOI 10.1016/j.jss.2004.10.011
  53. Unal S, 2003, PLAST RECONSTR SURG, V112, P1024, DOI 10.1097/01.PRS.0000076224.23190.52
  54. Vanlangenakker N, 2008, CURR MOL MED, V8, P207, DOI 10.2174/156652408784221306
  55. Varga J, 2012, ANN TRANSPL, V17, P11
  56. Wang SF, 2003, WORLD J GASTROENTERO, V9, P1866
  57. Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939
  58. YUE TL, 1994, ANN NY ACAD SCI, V738, P230
  59. ZIMMERMAN BJ, 1994, AM J MED SCI, V307, P284, DOI 10.1097/00000441-199404000-00009